Comparative Pharmacology
Head-to-head clinical analysis: FACTREL versus SUPPRELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTREL versus SUPPRELIN.
FACTREL vs SUPPRELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; stimulates pituitary release of LH and FSH initially, then suppresses gonadotropin secretion after chronic administration due to receptor downregulation.
Synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH) that acts as a potent inhibitor of gonadotropin secretion. Initially stimulates, then suppresses pituitary gonadotropin release (LH and FSH), leading to decreased testosterone and estrogen production.
100 mcg subcutaneously or 100 mcg intravenously, single dose for pituitary stimulation testing.
50 mcg subcutaneously once daily for the first month, then 25 mcg subcutaneously once daily for maintenance. Alternatively, 7.5 mg intramuscularly once monthly.
None Documented
None Documented
Terminal elimination half-life is approximately 30-45 minutes. Short half-life necessitates continuous or repeated administration for sustained therapeutic effect.
Terminal elimination half-life is approximately 4-6 hours following subcutaneous administration; this supports once-daily dosing.
Primarily renal (95% as unchanged drug and metabolites). Fecal excretion accounts for <5%.
Primarily renal, with approximately 70-80% of histrelin excreted unchanged in urine; biliary/fecal excretion accounts for about 20-30%.
Category C
Category C
GnRH Agonist
GnRH Agonist